Darl D. Flake
YOU?
Author Swipe
Multiyear Clinical Outcomes of Cancers Diagnosed Following Detection by a Blood-Based Multicancer Early Detection Test Open
In the US, <20% of cancers are diagnosed by standard-of-care (SoC) screening. Multicancer early detection (MCED) tests offer the opportunity to expand cancer screening. Understanding the characteristics and clinical outcomes of MCED-detect…
External validation of a multi-biomarker-based score for predicting risk of cardiovascular disease in patients with rheumatoid arthritis Open
Background A multi-biomarker disease activity (MBDA)-based cardiovascular disease (CVD) risk score was developed and internally validated in a Medicare cohort to predict 3-year risk for myocardial infarction (MI), stroke or CVD death in pa…
Outcomes Following a False-Positive Multi-Cancer Early Detection Test: Results from DETECT-A, the First Large, Prospective, Interventional MCED Study Open
Guideline recommended standard of care screening is available for four cancer types; most cancer-related deaths are caused by cancers without standard of care screening. DETECT-A is the first prospective interventional trial evaluating a m…
View article: Supplemental Figure 7 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Supplemental Figure 7 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes Open
Supplemental Figure 7 shows a lesion from the posterior shoulder of a 54 year old male was classified as compound dysplastic nevus with severe atypia. Melanoma could not be excluded on histopathologic examination. The score was +4.1. This …
View article: Supplemental Figure 2 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Supplemental Figure 2 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes Open
Supplemental Figure 2 shows a lesion from the right upper back of a 71 year old male that was classified as a superficial spreading melanoma ex nevus (Breslow thickness 0.69 mm, mitotic index 1/mm2,ulceration absent). The score was +4.1 Me…
View article: Supplemental Figure 7 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Supplemental Figure 7 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes Open
Supplemental Figure 7 shows a lesion from the posterior shoulder of a 54 year old male was classified as compound dysplastic nevus with severe atypia. Melanoma could not be excluded on histopathologic examination. The score was +4.1. This …
View article: Supplemental Figure 2 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Supplemental Figure 2 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes Open
Supplemental Figure 2 shows a lesion from the right upper back of a 71 year old male that was classified as a superficial spreading melanoma ex nevus (Breslow thickness 0.69 mm, mitotic index 1/mm2,ulceration absent). The score was +4.1 Me…
View article: Supplemental Figure 1 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Supplemental Figure 1 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes Open
Supplemental Figure 1 shows the distribution of gene expression scores in the overall cohort.
View article: Supplemental Figure 5 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Supplemental Figure 5 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes Open
Supplemental Figure 5 shows a lesion from the back of a 43 year old female was classified as a superficial spreading melanoma arising within a pre-existing dysplastic nevus (Breslow thickness 1.6 mm, mitotic index 0/mm2, ulceration absent)…
View article: Supplemental Figure 6 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Supplemental Figure 6 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes Open
Supplemental Figure 6 shows a lesion from the face of a 73 year old male was classified as a desmoplastic melanoma, pure type (Breslow thickness at least 1.2 mm, mitotic index 0/mm2, ulceration absent). The score was -2.6 (false negative).…
View article: Supplemental Figure 3 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Supplemental Figure 3 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes Open
Supplemental Figure 3 shows a lesion from the forehead of a 57 year old male that was classified as lentigo maligna melanoma (Breslow thickness 1.0 mm, mitotic index 0/mm2, ulceration absent). The lesion was completely excised. The score w…
View article: Supplemental Figure 4 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Supplemental Figure 4 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes Open
Supplemental Figure 4 shows a lesion from the posterior thigh of a 70 year old female that was classified as a nodular melanoma, nevoid type (Breslow thickness 1.25 mm, mitotic index 2/mm2, ulceration absent). The score was +6.6. Brain met…
View article: Supplemental Figure 3 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Supplemental Figure 3 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes Open
Supplemental Figure 3 shows a lesion from the forehead of a 57 year old male that was classified as lentigo maligna melanoma (Breslow thickness 1.0 mm, mitotic index 0/mm2, ulceration absent). The lesion was completely excised. The score w…
View article: Data from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Data from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes Open
Background: Histopathologic examination alone can be inadequate for diagnosis of certain melanocytic neoplasms. Recently, a 23-gene expression signature was clinically validated as an ancillary diagnostic test to differentiate benign nevi …
View article: Supplemental Figure 4 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Supplemental Figure 4 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes Open
Supplemental Figure 4 shows a lesion from the posterior thigh of a 70 year old female that was classified as a nodular melanoma, nevoid type (Breslow thickness 1.25 mm, mitotic index 2/mm2, ulceration absent). The score was +6.6. Brain met…
View article: Data from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Data from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes Open
Background: Histopathologic examination alone can be inadequate for diagnosis of certain melanocytic neoplasms. Recently, a 23-gene expression signature was clinically validated as an ancillary diagnostic test to differentiate benign nevi …
View article: Supplemental Figure 5 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Supplemental Figure 5 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes Open
Supplemental Figure 5 shows a lesion from the back of a 43 year old female was classified as a superficial spreading melanoma arising within a pre-existing dysplastic nevus (Breslow thickness 1.6 mm, mitotic index 0/mm2, ulceration absent)…
View article: Supplemental Figure 6 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Supplemental Figure 6 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes Open
Supplemental Figure 6 shows a lesion from the face of a 73 year old male was classified as a desmoplastic melanoma, pure type (Breslow thickness at least 1.2 mm, mitotic index 0/mm2, ulceration absent). The score was -2.6 (false negative).…
View article: Supplemental Figure 1 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Supplemental Figure 1 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes Open
Supplemental Figure 1 shows the distribution of gene expression scores in the overall cohort.
Separation of Points and Interval Estimation in Mixed Dose-Response Curves with Selective Component Labeling Open
This dissertation develops, applies, and investigates new methods to improve the analysis of logistic regression mixture models. An interesting dose-response experiment was previously carried out on a mixed population, in which the class m…
View article: The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation
The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation Open
The CCR score accurately and precisely prognosticates metastasis and adds clinically actionable information relative to guideline-recommended therapies based on NCCN risk in men undergoing dose-escalated RT with or without ADT. For men wit…
Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy Open
Background Validation of biomarker‐based prognostic models to improve risk stratification in men with localized prostate cancer (PrCa) remains a clinical need. It has previously been shown that the cell cycle progression (CCP) test provide…
Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy Open
Patients with CCR scores below the multimodality threshold (2.112) may safely forgo multimodality therapy. The CCR score can be used as a decision aid to counsel men whether or not single-modality therapy would be sufficient for their inte…
Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer Open
CCP was a better predictor of both tumor grade and subsequent patient management than was PI-RADS. Even in the context of targeted biopsy, molecular information remains essential to ensure precise risk assessment for men with newly diagnos…
View article: Clinical Validity of a Gene Expression Signature in Diagnostically Uncertain Neoplasms
Clinical Validity of a Gene Expression Signature in Diagnostically Uncertain Neoplasms Open
Aim: Evaluate the accuracy of a 23-gene expression signature in differentiating benign nevi from melanoma by comparing test results with clinical outcomes. Materials & methods: Seven dermatopathologists blinded to gene expression test resu…